2026-09-18T17:35:15Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/1527122023-11-03T03:04:51Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Greenwood, Veronique
Tsann, Abdullahi
Massachusetts Institute of Technology. Program in Comparative Media Studies/Writing
Massachusetts Institute of Technology. Graduate Program in Science Writing
2023-11-02T20:10:16Z
2023-11-02T20:10:16Z
2023-09
2023-06-08T15:17:33.383Z
https://hdl.handle.net/1721.1/152712
For decades, a dearth of scientific research, inadequate treatment and diagnostic tools have slowed progress in the fight to control tuberculosis globally. Scientists have developed important drugs, such as isoniazid, rifampin, and pyrazinamide, against the disease. But these drugs must be taken for several months, are sometimes ineffective, and can cause debilitating side effects. What’s more, if people don’t finish their treatments, it can lead to multidrug-resistant tuberculosis (MDR-TB), a form of the disease that is resistant to two of the four common drugs against TB, or, even more worryingly, extensively drug-resistant tuberculosis (XDR-TB), a form of the disease against which broader anti-TB drugs are powerless. Now, advances in immunology, chemistry, and biomolecular engineering are helping scientists to gain better insight into the complex cellular processes of Mycobacterium tuberculosis and the disease it causes. This could pave the way for the development of innovative diagnostics, vaccines, and new treatments for these tuberculosis superbugs. This thesis examines why tuberculosis kill millions of people till this day and scientists’ best efforts alone can’t win the war.
S.M.
Massachusetts Institute of Technology
In Copyright - Educational Use Permitted
Copyright retained by author(s)
https://rightsstatements.org/page/InC-EDU/1.0/
The Consumer of Humans
Thesis
application/pdf
Master
Master of Science in Science Writing
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="e54f5c4a-06ec-4ae3-bc45-7e04a191214b">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Title>The Consumer of Humans</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2023-09</PublicationDate>
<Authors>
<Author>
<DisplayName>Tsann, Abdullahi</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>https://rightsstatements.org/page/InC-EDU/1.0/</License>
<Abstract>For decades, a dearth of scientific research, inadequate treatment and diagnostic tools have slowed progress in the fight to control tuberculosis globally. Scientists have developed important drugs, such as isoniazid, rifampin, and pyrazinamide, against the disease. But these drugs must be taken for several months, are sometimes ineffective, and can cause debilitating side effects. What’s more, if people don’t finish their treatments, it can lead to multidrug-resistant tuberculosis (MDR-TB), a form of the disease that is resistant to two of the four common drugs against TB, or, even more worryingly, extensively drug-resistant tuberculosis (XDR-TB), a form of the disease against which broader anti-TB drugs are powerless. Now, advances in immunology, chemistry, and biomolecular engineering are helping scientists to gain better insight into the complex cellular processes of Mycobacterium tuberculosis and the disease it causes. This could pave the way for the development of innovative diagnostics, vaccines, and new treatments for these tuberculosis superbugs. This thesis examines why tuberculosis kill millions of people till this day and scientists’ best efforts alone can’t win the war.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>